Netherlands· NL-cd49b98d1847

Venclyxto AbbVie 100 mg filmomhulde tabletten

A venetoclax product containing venetoclax, registered in Netherlands by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.

ATC L01XX52

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about venetoclaxAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Venetoclax is registered in 14 of 19 countries.

Countries holding a registration under ATC L01XX52 (venetoclax), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search venetoclax products by name

Venetoclax · ATC L01XX52

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of venetoclax costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $226.72 in Switzerland to $1527.13 in France — a ×6.7 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Venetoclax · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

FR France$1527.13
CH Switzerland$226.72

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: VENETOCLAX
Manufacturer: AbbVie Deutschland GmbH & Co. KG
Country: Netherlands (NL)
ATC code: L01XX52
ATC class: Venetoclax
Defined daily dose: 0.4 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/16/1138

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

338 interactions on record for venetoclax.

Graded by severity as the source publishes them — 168 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check venetoclax against other medicines How interaction checks work

Venetoclax · interactions on record

338 records

168 severe
168 moderate
2 minor

Most severe, free to view

AprepitantA04AD12severe
RolapitantA04AD14severe
FidaxomicinA07AA12severe
EliglustatA16AX10severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Venetoclax in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All venetoclax products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

United Kingdom (Northern Ireland) · Venclyxto
Iceland · Venclyxto
Liechtenstein · Venclyxto
Norway · Venclyxto

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/5645f836-5177-4243-8a17-c0d125043108
GET /v1/drugs/5645f836-5177-4243-8a17-c0d125043108?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Venetoclax",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp118451",
  "excipients": [
    "CALCIUMWATERSTOFFOSFAAT 0-WATER (E 341)",
    "COPOVIDON (E 1208)",
    "IJZEROXIDE GEEL (E 172)",
    "MACROGOL 3350",
    "NATRIUMSTEARYLFUMARAAT",
    "POLYSORBAAT 80 (E 433)",
    "POLYVINYLALCOHOL (E 1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "VENETOCLAX"
  ],
  "leaflet_url": null,
  "authorised_at": "2016/12/05",
  "procedure_number": "EMEA/H/C/004106",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/16/1138",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about venetoclax.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console